Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers

Phase 1 Completed 60 enrolled Medicines Development for Global Health

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will investigate the effect of a single oral dose of moxidectin on the QT interval associated with moxidectin plasma concentrations. The effect of moxidectin on other ECG intervals, and on safety, will also be assessed, as will preliminary pharmacokinetics and metabolism

Timeline

Start: 2017-01
Primary completion: 2017-03
Completion: 2017-05

Publications

Kinrade SA, Mason JW, Sanabria CR, Rayner CR, Bullock JM, Stanworth SH, Sullivan MT. Evaluation of the Cardiac Safety of Long-Acting Endectocide Moxidectin in a Randomized Concentration-QT Study. Clin Transl Sci. 2018 Nov;11(6):582-589. doi: 10.1111/cts.12583. Epub 2018 Sep 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Moxidectin	Other / unclassified	4 mg	Oral
Subject	Moxidectin	Other / unclassified	8 mg	Oral
Subject	Moxidectin	Other / unclassified	16 mg	Oral
Subject	Moxidectin	Other / unclassified	24 mg	Oral
Subject	Moxidectin	Other / unclassified	36 mg	Oral

Indications

No indication recorded.